Drug intelligence / Profile preview

AST-0752

Development stage: Preclinical
Lead developer: Aston Sci
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular (inferred; Typical For mRNA Vaccines)

Overview

AST-0752 is a preclinical mRNA-based therapeutic vaccine developed by Aston SCI, targeting Trop-2 (tumor-associated calcium signal transducer 2), a tumor-associated antigen. The vaccine encodes multiple MHC class II epitopes of Trop-2 designed to elicit CD4+ Th1-specific immune responses against solid tumors. Its primary indication is for the treatment of neoplasms, specifically solid tumors. The drug's mechanism involves inhibiting Trop-2 function through immune-mediated mechanisms, aiming to enhance anti-tumor immunity in cancers expressing this antigen[1][4].

Other names: AST 0752AST0752AST-0752AST-07XAST07XAST 07X

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on AST-0752.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-0752.

Explore the full profile